PDF(Pubmed)
Abstract：
The cardiotoxicity of osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, has been recently reported when treating EGFR mutation-positive non-small cell lung cancer. In this report, we describe a case of an 81-year-old female patient diagnosed with Takotsubo syndrome (TTS). TTS occurred despite the patient receiving osimertinib retreatment at reduced doses and having no history of cardiac or respiratory disease. The findings of this case suggest that clinicians should consider the possibility of TTS induced by osimertinib.
摘要：
奥希替尼的心脏毒性，表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂，最近有报道称治疗EGFR突变阳性的非小细胞肺癌。在这份报告中,我们描述一例81岁女性患者,诊断为Takotsubo综合征(TTS).尽管患者接受奥希替尼减量再治疗且无心脏病或呼吸系统疾病史，但仍发生TTS。该病例的结果表明，临床医生应考虑奥希替尼诱导TTS的可能性。
